This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism

This study has been completed.
Information provided by:
Gulhane School of Medicine Identifier:
First received: April 19, 2010
Last updated: NA
Last verified: May 2008
History: No changes posted
The purpose of this study is investigating the effect of testosterone treatment on paraoxonase level in male patients with hypogonadotrophic hypogonadism

Condition Intervention Phase
Hypogonadism Drug: Sustanon Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Phase IV Study to Investigate the Effect of Testosterone Treatment on Paraoxonase Level in Male Patients With Hypogonadotrophic Hypogonadism

Resource links provided by NLM:

Further study details as provided by Gulhane School of Medicine:

Primary Outcome Measures:
  • paraoxonase level after testosterone treatment

Enrollment: 32
Study Start Date: June 2008
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: testosterone replacement therapy Drug: Sustanon
250 mg/21 days
Other Name: no name


Ages Eligible for Study:   20 Years to 25 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Volunteers patients with hypogonadism

Exclusion Criteria:

  • Coronary heart disease
  • Other pituitary/hypothalamic disorders or other non-hypogonadism diseases
  • None was receiving vitamins, lipid-lowering drugs, or other medications known to interfere with PON1 activity, lipid profile, or gonadal function
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01107067

Ankara, Turkey, 06600
Sponsors and Collaborators
Gulhane School of Medicine
  More Information

Responsible Party: Gulhane School of Medicine Department of Endocrinology and Metabolism Identifier: NCT01107067     History of Changes
Other Study ID Numbers: aa001
Study First Received: April 19, 2010
Last Updated: April 19, 2010

Keywords provided by Gulhane School of Medicine:

Additional relevant MeSH terms:
Gonadal Disorders
Endocrine System Diseases
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents processed this record on September 21, 2017